guest ::
| Home > Publications database > The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects. > print |
| Home > Publications database > The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects. > print |
| 001 | 307462 | ||
| 005 | 20260212120741.0 | ||
| 024 | 7 | _ | |a 10.1053/j.semnuclmed.2025.12.003 |2 doi |
| 024 | 7 | _ | |a pmid:41453817 |2 pmid |
| 024 | 7 | _ | |a 0001-2998 |2 ISSN |
| 024 | 7 | _ | |a 1558-4623 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-03061 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Civan, Caner |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1767095852_1386405 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a PSMA-PET has become a pivotal imaging method for staging and restaging of prostate cancer. Risk stratification of the disease is a crucial for the patients to receive most appropriate treatment, and for the clinicians to follow the patients more precisely. PSMA-PET provides non-invasive biomarkers for the risk assessment of prostate cancer, offering prediction of clinical outcomes. PROMISE criteria have been developed as comprehensive and integrated framework demonstrating association with overall survival. In this review, we aim to provide a brief update of the prognostic value of PSMA-PET for risk assessment in prostate cancer. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Assessment |2 Other |
| 650 | _ | 7 | |a CT |2 Other |
| 650 | _ | 7 | |a PET |2 Other |
| 650 | _ | 7 | |a PSMA |2 Other |
| 650 | _ | 7 | |a Prostate cancer |2 Other |
| 650 | _ | 7 | |a Risk |2 Other |
| 700 | 1 | _ | |a Karpinski, Madeleine J |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Rahbar, Kambiz |b 2 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 4 |
| 773 | _ | _ | |a 10.1053/j.semnuclmed.2025.12.003 |g p. S0001299825001813 |0 PERI:(DE-600)2133379-8 |p nn |t Seminars in nuclear medicine |v nn |y 2025 |x 0001-2998 |
| 856 | 4 | _ | |y OpenAccess |u https://inrepo02.dkfz.de/record/307462/files/1-s2.0-S0001299825001813-main.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://inrepo02.dkfz.de/record/307462/files/1-s2.0-S0001299825001813-main.pdf?subformat=pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:307462 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-27 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SEMIN NUCL MED : 2022 |d 2024-12-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-27 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-27 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-27 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-27 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-27 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|